A uniquely distributed purpuric drug eruption from acalabrutinib.

Truong, Kelvin; Bhattacharyya, Abir; Kim, Jennifer; Wells, Jillian

Truong, Kelvin; Bhattacharyya, Abir; Kim, Jennifer; Wells, Jillian.

Afiliação

Truong K; Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia.
Bhattacharyya A; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Kim J; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Wells J; Department of Haematology, Westmead Hospital, Westmead, New South Wales, Australia.

Australas J Dermatol ; 63(2): e142-e144, 2022 May.

Article em En | MEDLINE | ID: mdl-35072264

Assuntos

Toxidermias; Púrpura; Adenina; Tirosina Quinase da Agamaglobulinemia; Benzamidas; Toxidermias/etiologia; Humanos; Piperidinas; Inibidores de Proteínas Quinases/efeitos adversos; Pirazinas; Qualidade de Vida

Palavras-chave

Acalabrutinib; Bruton's tyrosine kinase inhibitor; EGFR inhibitor; Purpuric drug eruption; Small vessel vasculitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google